Dr Athanasios Papadopoulos joined Emergex in February 2019. He is responsible for providing leadership and direction on the development of Emergex’s growing pipeline of vaccines.
Athanasios has extensive regulatory and clinical development expertise gained through more than 20 years of experience in industry.
He previously held senior leadership roles at multinational pharma companies Sanofi and Novartis, where he led scientific strategy and full integration of clinical development programs for vaccines Dengvaxia® (against Dengue fever) and Bexsero® (against Meningitis B), respectively.
He has also made significant contributions to product development in therapeutic areas such as autoimmune diseases, oncology and cardiovascular conditions, including filing several submissions to regulatory authorities worldwide e.g. FDA, EMA.
Athan is a GMC-registered medical doctor, originally trained in Greece as a clinical bio-pathology specialist.